Investigation Reveals Unreported Child Death in China’s First Brain-Directed CRISPR Trial

A six-year-old girl dies in March 2025 after receiving an experimental gene-editing treatment at Shanghai Xinhua Hospital, sparking intense ethical and regulatory scrutiny. The child's parents contribute $860,000 to fund the therapy, which leads to a fatal immune reaction. Lead researcher Zilong Qiu and his team omit the death and prior animal safety issues from a 2026 Nature paper. The hospital faces a minor $3,600 fine, highlighting gaps in China's oversight of investigator-initiated trials.

Unreported gene-editing trial death

• ▪A six-year-old girl died in March 2025 days after receiving an experimental gene-editing treatment at Shanghai Xinhua Hospital in China.
• ▪The experimental therapy was designed to correct a genetic mutation affecting the six-year-old girl's neurodevelopment.
• ▪The six-year-old girl died of a severe immune reaction seven days after receiving an infusion of viruses carrying a base-editing therapy into her spinal fluid.

Chinese clinical trial oversight

• ▪Investigator-initiated trials in China grew 11-fold from 2015 to 2023, exceeding 1,000 studies.
• ▪China revamped cell and gene therapy regulations in June 2026, restricting trials to specific hospitals and banning institutions from charging patients clinical research fees.
• ▪Shanghai Xinhua Hospital allowed the experimental gene-editing trial to proceed under an investigator-initiated trial pathway that does not require approval from China's national drug regulator.

Medical ethics violations

• ▪Seven genetics, virology, and bioethics experts stated that the research team downplayed trial risks to the parents and overlooked safety signals in animal studies.
• ▪The parents of the deceased six-year-old girl contributed $860,000 to fund the research and clinical work for her experimental gene-editing treatment.
• ▪Shanghai Xinhua Hospital was fined approximately $3,600 for its failures in the trial, and the overseeing physician, Yongguo Yu, received verbal counseling.

Transparency failures in research

• ▪The ClinicalTrials.gov registry entry for the Shanghai Xinhua Hospital gene-editing study has not been updated for more than a year.
• ▪The research team led by Zilong Qiu published animal studies related to the therapy in Nature in early 2026 but omitted the patient's death and previous monkey experiment safety issues.